$92.20
0.32% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Verona Pharma plc Sponsored ADR Stock price

$92.20
+24.63 36.45% 1M
+50.78 122.60% 6M
+45.76 98.54% YTD
+76.64 492.55% 1Y
+87.00 1,673.08% 5Y
+78.70 582.96% 10Y
+78.70 582.96% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.30 0.32%
ISIN
US9250501064
Symbol
VRNA
Sector
Industry

Key metrics

Market capitalization $7.87b
Enterprise Value $7.71b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 65.08
P/S ratio (TTM) P/S ratio 66.43
P/B ratio (TTM) P/B ratio 277.13
Revenue (TTM) Revenue $118.54m
EBIT (operating result TTM) EBIT $-137.75m
Free Cash Flow (TTM) Free Cash Flow $-121.25m
Cash position $401.42m
EPS (TTM) EPS $-0.25
P/E forward 329.29
P/S forward 19.24
EV/Sales forward 18.85
Short interest 8.74%
Show more

Is Verona Pharma plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Verona Pharma plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

Buy
100%

Financial data from Verona Pharma plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
119 119
-
100%
- Direct Costs 5.99 5.99
-
5%
113 113
-
95%
- Selling and Administrative Expenses 198 198
224% 224%
167%
- Research and Development Expense 52 52
247% 247%
44%
-137 -137
90% 90%
-115%
- Depreciation and Amortization 1.09 1.09
40% 40%
1%
EBIT (Operating Income) EBIT -138 -138
90% 90%
-116%
Net Profit -164 -164
158% 158%
-138%

In millions USD.

Don't miss a Thing! We will send you all news about Verona Pharma plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verona Pharma plc Sponsored ADR Stock News

Positive
Seeking Alpha
4 days ago
Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projects Verona Pharma's sales to reach $1 billion by 2028, fueled by its safety profile and the unmet needs of those 398 million COPD sufferers worldwide. Global expansion, robust patent protection, and...
Positive
The Motley Fool
9 days ago
If you want to achieve significant gains in the stock market, you'll probably want to plan to hold on and remain invested for many years, or even decades. But in some cases, big payoffs can come much faster than that.
Neutral
GlobeNewsWire
24 days ago
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:
More Verona Pharma plc Sponsored ADR News

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO David Zaccardelli
Employees 209
Founded 2005
Website www.veronapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today